Patent & Trade Mark
Attorneys
We are
Experts in Navigating IP in the Asia Pacific Region
Working with clients in
Thanks to many years of global experience, FB Rice has a network of trusted advisors in all key jurisdictions. We turn to those advisors when assisting our clients to promote their interests.

For specific information on our Asia Pacific capability, click here.
One door to South East Asia
For a seamless service for filing and prosecuting patent and trade mark applications in South East Asia, click here.
Connie Merlino

Partner

Connie Merlino
“The patentability of software remains a grey area under Australian law and around the world. But patenting software is possible in the right hands. Our Information Communications and Technology team at FB Rice are experts at ensuring that software inventions are robustly protected worldwide.”
“The patentability of software remains a grey area under Australian law and around the world. But patenting software is possible in the right hands. Our Information Communications and Technology team at FB Rice are experts at ensuring that software inventions are robustly protected worldwide.”
New Zealand to introduce a one-year grace period
New Zealand looks set to introduce a new one-year grace period into the Patents Act 2013 after ratifying the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) on 25 October 2018.
New Zealand looks set to introduce a new one-year grace period into the Patents Act 2013 after ratifying the Comprehensive and Progressive Agreement for Trans-Pacific Partnership (CPTPP) on 25 October 2018.
25 February 2019
Australia: trade mark non-use grace period scaled back
On 24 February 2019 the remainder of a number of IP legislation improvements under the Intellectual Property Laws Amendment (Productivity Commission Response Part 1 and Other Measures) Act 2018 will come into force. The amendments are designed to streamline the administration of Australia’s IP system. For trade mark owners, as of 24 February 2019, an amendment to section 93 of the Trade Marks Act 1995 (the Act) reduces the grace period for which a trade mark will become vulnerable to removal or partial removal (limitation) for non-use.
On 24 February 2019 the remainder of a number of IP legislation improvements under the Intellectual Property Laws Amendment (Productivity Commission Response Part 1 and Other Measures) Act 2018 will come into force. The amendments are designed to streamline the administration of Australia’s IP system. For trade mark owners, as of 24 February 2019, an amendment to section 93 of the Trade Marks Act 1995 (the Act) reduces the grace period for which a trade mark will become vulnerable to removal or partial removal (limitation) for non-use.
Dae Woong Oh

Patent Attorney

Dae Woong Oh
Dae is a qualified Australian and Korean patent attorney with extensive experience in the field of patent searching and analysis. Dae regularly works with FB Rice attorneys conducting business with Korean firms, as well as providing valuable cultural insight into managing intellectual property issues in the Korean system.
Dae is a qualified Australian and Korean patent attorney with extensive experience in the field of patent searching and analysis. Dae regularly works with FB Rice attorneys conducting business with Korean firms, as well as providing valuable cultural insight into managing intellectual property issues in the Korean system.
29 March 2018
Did you say ‘a shortage of cocoa beans’?
The thought of the cocoa bean extinction on the horizon due to climate change gives me the shivers. Without cocoa beans, there is no chocolate! Don’t panic; science and innovation is working towards future-proofing the chocolate industry.
The thought of the cocoa bean extinction on the horizon due to climate change gives me the shivers. Without cocoa beans, there is no chocolate! Don’t panic; science and innovation is working towards future-proofing the chocolate industry.
Expect the unexpected | Patenting antibodies in Asia
Monoclonal antibodies are important human therapeutic agents and represent some of the largest selling drugs in the world. Patents relating to antibodies are treated differently to some other compounds in some jurisdictions. This article touches on some of the important requirements for antibody patenting in some major Asian jurisdictions, namely Japan, China and South Korea.
Monoclonal antibodies are important human therapeutic agents and represent some of the largest selling drugs in the world. Patents relating to antibodies are treated differently to some other compounds in some jurisdictions. This article touches on some of the important requirements for antibody patenting in some major Asian jurisdictions, namely Japan, China and South Korea.